MedTrace Logo

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03282344 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2025-10-01

No results posted yet for this study

Summary

The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.

Conditions

  • SARCOMA

Interventions

DRUG

NKTR-214

0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.

DRUG

Nivolumab

360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.

Sponsors & Collaborators

Principal Investigators

  • Sandra D'Angelo, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-12
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282344 on ClinicalTrials.gov